10.94

0.18% 0.02

After Hours: 10.76 -0.18 -1.65%

Sagimet Biosciences Inc (SGMT)

Overview News Price History Discussions Forecast

Sagimet Biosciences Inc stock is traded at $10.94, with a volume of 1.25M. It is up +0.18% in the last 24 hours and up +36.92% over the past month. Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.

Previous Close:

$10.92

Open:

$10.79

24h Volume:

1.25M

Relative Volume:

1.03

Market Cap:

$680.02M

Revenue:

$2.00M

Net Income/Loss:

$-43.51M

P/E Ratio:

-8.1551

EPS:

-1.3415

Net Cash Flow:

$-39.73M

1W Performance:

+3.70%

1M Performance:

+36.92%

6M Performance:

+89.93%

1Y Performance:

+50.90%

1-Day Range:

$10.53

$10.98

1-Week Range:

$10.15

$11.24

52-Week Range:

$4.50

$11.24

Sagimet Biosciences Inc Stock (SGMT) Company Profile

Name

Sagimet Biosciences Inc

Sector

Healthcare (1074)

Industry

Biotechnology (600)

Phone

(650) 561-8600

Address

155 BOVET RD., SUITE 303, SAN MATEO

Employee

Twitter

Next Earnings Date

2026-08-12

Latest SEC Filings

SGMT's Discussions on Twitter

Compare SGMT vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SGMT Sagimet Biosciences Inc	10.94	632.78M	2.00M	-43.51M	-39.73M	-1.3415
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Sagimet Biosciences Inc Stock (SGMT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-26-26	Initiated	Rodman & Renshaw	Buy
Feb-03-26	Initiated	Guggenheim	Buy
Jan-28-26	Initiated	Barclays	Equal Weight
Aug-11-25	Initiated	Wedbush	Outperform
Aug-07-25	Resumed	H.C. Wainwright	Buy
Jul-24-25	Initiated	Canaccord Genuity	Buy
Dec-06-24	Initiated	Oppenheimer	Outperform
Nov-12-24	Initiated	UBS	Buy
Jun-28-24	Downgrade	Goldman	Buy → Neutral
May-02-24	Initiated	H.C. Wainwright	Buy
Mar-25-24	Initiated	Leerink Partners	Outperform
Aug-08-23	Initiated	Goldman	Buy
Aug-08-23	Initiated	JMP Securities	Mkt Outperform
Aug-08-23	Initiated	Piper Sandler	Overweight
Aug-08-23	Initiated	TD Cowen	Outperform

View All

Sagimet Biosciences Inc Stock (SGMT) Latest News

Sep 05, 2026

SGMT Stock Surged 40% And Breached 200-DMA For The First Time In Nearly 3 Months – What’s Got Retail Buzzing? - Stocktwits

Sep 05, 2026

Sep 02, 2026

A drug developer's investor chat is set for Sept. 9 in New York - Stock Titan

Sep 02, 2026

Aug 27, 2026

Enterprise value to EBIT forward of Sagimet Biosciences Inc.Series A – NASDAQ:SGMT - TradingView

Aug 27, 2026

Aug 26, 2026

H.C. Wainwright Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Maintains Target Price $29 - Moomoo

Aug 26, 2026

Aug 25, 2026

Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial Of Denifanstat In Acne Toward Patient Enrollment In Q4 2026 - TradingView

Aug 25, 2026

Sagimet plans to start acne drug trial enrollment in Q4 - Investing.com India

Aug 25, 2026

Sagimet plans to start acne drug trial enrollment in Q4 By Investing.com - Investing.com Canada

Aug 25, 2026

JonesTrading Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Maintains Target Price $31 - Moomoo

Aug 25, 2026

Aug 20, 2026

Balyasny Asset Management L.P. Acquires Stake in Sagimet Bioscie - GuruFocus

Aug 20, 2026

Aug 18, 2026

Sagimet Biosciences Inc. Series A Common Stock (NASDAQ: SGMT) Stock Price, News & Analysis - Kalkine

Aug 18, 2026

Aug 17, 2026

Sagimet Biosciences Director George Kemble Exercises Options and Sells 350,987 Shares - Kalkine Media

Aug 17, 2026

Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Caledonian Record

Aug 17, 2026

Sagimet Biosciences Eyes U.S. Phase III Acne Study After Positive China Data - MarketBeat

Aug 17, 2026

Aug 15, 2026

Sagimet Biosciences (SGMT) Surges 13.7% to $10.55 as Biotech Momentum BuildsMFI Divergence - vinanet.vn

Aug 15, 2026

SGMT Q1 2026 Earnings: Narrower-than-Expected Loss Spurs 13.7% Stock RallyGrowth Acceleration Report - vinanet.vn

Aug 15, 2026

Dimensional Fund Advisors LP Acquires 135,178 Shares of Sagimet Biosciences Inc. $SGMT - MarketBeat

Aug 15, 2026

Sagimet Biosciences (NASDAQ:SGMT) Cut to "Sell" at Wall Street Zen - MarketBeat

Aug 15, 2026

Aug 14, 2026

SGMT (NASDAQ: SGMT) executive plans 350,987-share stock sale under Form 144 - Stock Titan

Aug 14, 2026

Sagimet Biosciences (NASDAQ:SGMT) Given New $29.00 Price Target at Citizens Jmp - MarketBeat

Aug 14, 2026

Citizens raises Sagimet stock price target to $29 on acne drug - Investing.com South Africa

Aug 14, 2026

Sagimet Biosciences (SGMT): Balyasny group discloses 5.93% ownership in Schedule 13G - Stock Titan

Aug 14, 2026

Aug 13, 2026

FDA Approves Sagimet Biosciences' IND for Phase 3 Denifanstat Acne Study - Kalkine Media

Aug 13, 2026

Sagimet Biosciences Receives US FDA Clearance for Phase 3 Acne Trial - marketscreener.com

Aug 13, 2026